Antibiotic Screen for Isoprenoid Pathway in B.anthracis

Information

  • Research Project
  • 6557002
  • ApplicationId
    6557002
  • Core Project Number
    R43AI053048
  • Full Project Number
    1R43AI053048-01
  • Serial Number
    53048
  • FOA Number
    RFA-AI-02-05
  • Sub Project Id
  • Project Start Date
    7/1/2002 - 22 years ago
  • Project End Date
    6/30/2003 - 21 years ago
  • Program Officer Name
    ZOU, LANLING
  • Budget Start Date
    7/1/2002 - 22 years ago
  • Budget End Date
    6/30/2003 - 21 years ago
  • Fiscal Year
    2002
  • Support Year
    1
  • Suffix
  • Award Notice Date
    7/1/2002 - 22 years ago

Antibiotic Screen for Isoprenoid Pathway in B.anthracis

DESCRIPTION (provided by applicant): Isoprenoid compounds form a large ubiquitous class of natural products that fulfill a wide variety of essential cellular functions in al living organisms. In eukaryotes, isoprenoid compounds are synthesized by a mevalonate (MVA) dependent pathway. However, in many bacteria, these compounds are synthesized by an alternative, MVA-independent route whose first committed intermediate is 2-methylerythritol 4-phosphate (MEP). Both pathways converge at isopentenyl diphosphate (IPP) and subsequent steps are similar in all organisms. Since the N EP pathway is absent in mammals, it is considered an attractive target for the development of novel antibiotics. The pathogen, Bacillus anthracis belongs to the MEP pathway class of organisms. We will prepare a transgenic bacterial E. coli host cell whose genome contains disruptions in a first endogenous gene in the N4EP pathway and a second endogenous gene which is located downstream of the first gene in the M P pathway. A transgene from B. anthracis that functionally replaces the disrupted downstream gene will be cloned into the cell. The growth of the host cell in the presence of test agent is then compared to a control culture to determine the activity of the test agent. Where the test agent renders the bacterial host cell inviable on media containing a chemical supplement to relieve the DXP block and viable on the media containing NIVA indicates that the test agent has the potential to be an effective antibacterial against B. anthracis.

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R43
  • Administering IC
    AI
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    98560
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    856
  • Ed Inst. Type
  • Funding ICs
    NIAID:98560\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    ECHELON BIOSCIENCES, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    SALT LAKE CITY
  • Organization State
    UT
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    84108
  • Organization District
    UNITED STATES